Fulcrum Therapeutics announced a partnership with the MedicAlert Foundation and the Sickle Cell Disease Association of America (SCDAA) to improve emergency department access to patient‑specific care plans for people living with sickle cell disease (SCD). The collaboration will provide SCD patients with a MedicAlert Smart Medical ID Card linked to a secure digital health profile. When the card’s QR code is scanned by emergency department personnel, clinicians can instantly view the patient’s physician‑approved pain plan, hematologist contact information, medications, allergies and other critical health data, aiming to reduce delays during acute pain crises.
The partnership builds on a pilot program launched in September 2023 by MedicAlert and SCDAA and expands the reach of the initiative. Fulcrum’s CEO Alex Sapir said, “At Fulcrum, we are committed not only to developing innovative therapies, but also to advancing solutions that improve the entire care journey for people living with SCD. Through this partnership, we hope to help solve some of the most pervasive challenges people living with SCD face and reduce delays in care when minutes matter most.” The collaboration aligns with Fulcrum’s focus on improving the overall care journey for its target population while supporting the development of its lead program, pociredir, an oral fetal hemoglobin inducer for SCD.
The partnership also addresses systemic challenges that SCD patients face in emergency departments, including long wait times, lack of provider knowledge, and potential bias. By providing a quick, reliable source of patient‑specific information, the initiative aims to mitigate these barriers and ensure that emergency clinicians can deliver timely, appropriate care.
Fulcrum’s financial context underscores the strategic value of the partnership. The company reported a Q4 2025 earnings per share of –$0.31, meeting analyst estimates, and a net loss of $74.9 million for the year ended December 31, 2025, compared with a $9.7 million loss for the prior year. Cash, cash equivalents, and marketable securities totaled $352.3 million as of 2025, providing a runway into 2029. The partnership demonstrates Fulcrum’s commitment to patient care beyond its drug pipeline and may strengthen stakeholder relationships amid a market that has focused on the company’s financial performance.
The initiative was welcomed by the Sickle Cell Disease Association of America. Regina Hartfield, President and CEO of SCDAA, said, “Too often, individuals living with SCD face barriers to receiving appropriate and compassionate care quickly during a pain crisis in the emergency department. This partnership represents an important step forward in this program, originally launched in 2023 between MedicAlert and SCDAA. Fulcrum’s commitment will enable us to broaden our reach into SCDAA’s membership and to the SCD community and will empower so many more individuals living with SCD with a trusted way to effectively share their care and/or pain plans and medical information with emergency clinicians, helping ensure their voices and needs are recognized when they seek care.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.